SEARCH:   Advanced

Blood, 28 May 2009, Vol. 113, No. 22, pp. 5401-5411. Prepublished online as a Blood First Edition Paper on April 6, 2009; DOI 10.1182/blood-2008-12-196543. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-12-196543v1 113/22/5401    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Noens, L. Articles by Abraham, I. Search for Related Content PubMed PubMed Citation Articles by Noens, L. Articles by Abraham, I. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 30, 2008 Accepted March 13, 2009 Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Lucien Noens, Marie-Anne van Lierde, Robrecht De Bock, Gregor Verhoef, Pierre Zachee, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Van Eygen, Karen MacDonald, Sabina De Geest, Tara Albrecht, and Ivo Abraham* UZ Gent, Gent, Belgium Novartis Pharma, Vilvoorde, Belgium ZNA Middelheim, Antwerpen, Belgium UZ Gasthuisberg, Leuven, Belgium ZNA Stuivenberg, Antwerpen, Belgium UZA, Antwerpen, Belgium Institut Jules Bordet, Bruxelles, Belgium Hopital St. Joseph, Gilly, Belgium AZ Groeninge, Kortrijk, Belgium Matrix45, Earlysville, VA, United States University of Basel, Institute of Nursing Science, Basel, Switzerland University of Virginia, School of Nursing, Charlottesville, VA, United States University of Arizona, College of Nursing, and Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, Tucson, AZ, United States * Corresponding author; email: iabraham{at}matrix45.com. Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being life-long, patient adherence is critical. The ADAGIO study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in CML patients; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, SD=23.8) than did those with optimal response (7.3%, SD=19.3, P=0.005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020